Printed from Voxsanity (voxsanity.com.au) — NCT07554846 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 3 Lung Cancer Trial, Not Yet Recruiting
NCT07554846
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged between 18 and 75 years old, of either gender.
- People diagnosed with non-small cell lung cancer at stage II or IIIA (using AJCC 8th edition staging) that can be removed by surgery, confirmed by tissue testing, and without certain genetic features (EGFR wild type and no ALK rearrangement).
- People with a good general level of physical functioning, scored 0 or 1 on a standard performance scale (ECOG PS).
- People who have at least one measurable area of cancer visible on scans, according to standard measurement guidelines (RECIST 1.1).
- People whose life expectancy is estimated to be at least 3 months.
- People whose major organ functions (such as heart, liver, and kidneys) are working normally, as tested within the 14 days before joining the trial.
- People whose overall lung capacity has been assessed by a surgeon as being able to tolerate the planned lung surgery.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a known allergy to anti-PD-1 monoclonal antibody medications or any of their ingredients.
- People who are currently taking part in another clinical trial and receiving experimental treatment.
- People who have previously received any systemic treatment (such as chemotherapy, targeted therapy, or immunotherapy) for their current stage II–III non-small cell lung cancer.
- People who have active tuberculosis (TB) and are currently being treated for it, or who received TB treatment within the past year before screening.
- People with uncontrolled or symptomatic high calcium levels in the blood above certain thresholds (confirm with trial site).
- People with an active, uncontrolled infection, including but not limited to acute pneumonia.
- People with uncontrollable severe epileptic seizures or a condition called superior vena cava syndrome.
- People who have previously had or currently have another type of cancer, with some exceptions such as certain treated skin cancers, breast or cervical carcinoma in situ, superficial bladder cancer, or other early-stage cancers that were fully treated with no signs of return.
- People with certain lung conditions, including interstitial pneumonia, idiopathic pulmonary fibrosis, organising pneumonia, drug-induced pneumonia, idiopathic pneumonia, signs of active pneumonia on a chest CT scan, or other moderate to severe lung diseases that seriously affect lung function.
- People known to have HIV infection (confirmed by a positive HIV antibody test).
- People with serious heart or cardiovascular conditions, such as significant heart failure (NYHA class 2 or above), unstable angina, unstable irregular heart rhythms, or a heart attack or stroke within the 6 months before joining the trial.
- People who have taken systemic immunosuppressive medications (such as corticosteroids or immune-suppressing drugs) for an active autoimmune disease within the past 2 years.
- People who received a live virus vaccine within 4 weeks before the trial starts.
- People who have previously had an organ transplant or a bone marrow/stem cell transplant from a donor.
- Women who are pregnant, breastfeeding, or who test positive for pregnancy before their first dose; or people capable of becoming pregnant (or whose partners could become pregnant) who are unwilling to use contraception during the trial.
- People whose participation may be unsuitable due to factors such as a psychiatric history, substance or drug abuse, inability to provide informed consent, or other significant medical conditions that could affect their ability to safely take part in or comply with the trial (confirm specific details with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 May 2030
Where this trial is recruiting
🇨🇳 China
Primary endpoints
3-year events-free survival (EFS) rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.